Drug Profile
Cafusertib
Alternative Names: Cafusertib HCl; Cafusertib hydrochlorideLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Protein-serine-threonine kinase inhibitors; Proto-oncogene protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in China (IV, Infusion)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (IV, Infusion)
- 11 Mar 2016 Phase-I development is ongoing in China